The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

When a house catches on fire, we assume that a smoke alarm inside will serve one purpose and one purpose only: warn the ...

For millions living with nerve pain, even a light touch can feel unbearable. Scientists have long suspected that damaged ...

For most of us, everyday life is characterized by a lack of movement. But those long hours sitting at a desk, commuting by ...

Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...

Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the ...

Meet L-serine, an essential amino acid that supports healthy brain function, improves memory, and keeps your neurons firing ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...